The stunningly rapid and steep decline in the valuation of one-time unicorn JUUL Labs has apparently taken a toll on another major early investor.
Chase Coleman’s Tiger Global Management recently told clients in its third quarter letter that it “marked down the position meaningfully in September,” acknowledging that the company “is facing increasing uncertainty on the regulatory front.”
This
